This inventor holds 1 USPTO granted patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Christopher C Lai: Innovator in Anticancer Therapeutics
Introduction
Christopher C Lai is a notable inventor based in Ellicott City, MD (US). He has made significant contributions to the field of cancer therapeutics through his innovative research and development of novel compounds.
Latest Patents
Christopher C Lai holds a patent for "Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use." This invention provides novel compounds that may serve as anticancer therapeutics. The compounds bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected phosphoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives have achieved both good efficacy and enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Furthermore, it offers a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents. Christopher C Lai has 1 patent.
Career Highlights
Christopher C Lai is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work focuses on developing innovative solutions to combat cancer through advanced therapeutic methods.
Collaborations
He has collaborated with notable colleagues, including Wenjian Qian and Jung Eun Park, to further enhance the impact of his research in the field of cancer therapeutics.
Conclusion
Christopher C Lai's contributions to the development of anticancer therapeutics highlight his role as an innovator in the medical field. His work continues to pave the way for new treatment options for cancer patients.